This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
You do not have access to the full text of this article, the first page of the PDF of this article appears above.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
February 2020
Volume 8, Issue 2
Volume 8, Issue 2
A Sampling of Highlights from the Literature
Jump to section
- Article
- Improving CAR T-cell therapy for solid tumors
- Targeting CD39 in cancer reveals an extracellular ATP- and inflammasome-driven tumor immunity
- An intra-tumoral niche maintains and differentiates stem-like CD8+ T cells
- Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
- The PD-L1:CD80 cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways
- GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment
- Info & Metrics
Advertisement